Psoriasis News and Research

Latest Psoriasis News and Research

Stoptober campaign focuses on skin disease research

Stoptober is a UK-wide campaign to get the nation to quit smoking. We, the British Skin Foundation, are asking that Stoptober participants get a friends, family & colleagues to sponsor your efforts and raise some money for skin disease research at the same time.

22 Sep 2015

Immune Pharmaceuticals’ CEO establishes stock trading plan

Immune Pharmaceuticals, Inc. announced today that its Chief Executive Officer, Dr. Daniel Teper, has established a stock trading plan with respect to the purchases of up to an aggregate of $250,000 of shares of Immune common stock in accordance with Rule 10b5-1 under the Exchange Act and other applicable federal securities laws and regulations adopted by the Securities and Exchange Commission.

16 Sep 2015

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2015 and updates on its drug development programs.

28 Aug 2015

Janus collaborates with Roche to develop TLR inhibitor to address several autoimmune diseases

Janus Biotherapeutics today announced that they have entered into a collaboration with Roche for the development of a small molecule toll-like receptor (TLR) inhibitor with the potential to address several autoimmune diseases. TLRs are an important class of proteins that play a key role in the innate immune system.

20 Aug 2015

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS).

20 Aug 2015

Risk of hepatobiliary cancer higher in women with intrahepatic cholestasis of pregnancy

In a new study of more than 125,000 pregnant women in Sweden, researchers at the Sahlgrenska Academy found that the risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life is higher in women with intrahepatic cholestasis of pregnancy (ICP) than in women without this condition.

12 Aug 2015

Scientific consensus paper highlights health benefits of UV exposure and vitamin D

The Journal of the American College of Nutrition is pleased to offer Open Access to a scientific consensus paper, Sunlight and Vitamin D: Necessary for Public Health, authored by scientists from the University of California, San Diego, Creighton University, Boston University Medical Center, and the Medical University of South Carolina, along with other research contributors.

7 Aug 2015

Results of IPC survey identifying 21 psoriasis research priorities published in British Journal of Dermatology

The British Journal of Dermatology has published online the results of an International Psoriasis Council (IPC) survey identifying 21 psoriasis research priorities. The results will also appear in a future print edition of the journal.

6 Aug 2015

World Health Organization recognizes unique pharmacological nature of Can-Fite's CF101, grants new generic name

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced that the World Health Organization's International Nonproprietary Name group has accepted the proposed generic name "piclidenoson" for its lead drug candidate, CF101.

29 Jul 2015

Does dandruff cause psychological distress? An interview with Dr Anjali Mahto

Dandruff is a common chronic scalp disorder that is characterised by flaking of the skin of the scalp. As skin cells die, they are shed from the scalp surface. For some people, however, excessive flaking occurs, resulting in dandruff.

28 Jul 2015

National Psoriasis Foundation introduces patient-centered research network

For the first time, people with psoriasis and psoriatic arthritis can contribute directly to the future of research into these chronic, systemic autoimmune diseases through the National Psoriasis Foundation's patient-centered research network called Citizen Pscientist.

25 Jul 2015

AnaptysBio announces completion of oversubscribed $40MM Series D financing round

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology, today announced the completion of an oversubscribed $40MM Series D financing round.

15 Jul 2015

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Results published today in The New England Journal of Medicine from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared psoriasis or minimal psoriasis at week 16, the study's primary endpoint.

9 Jul 2015

Risk of hepatobiliary cancer, cardiovascular diseases later in life is higher in women with ICP

In a new study of more than 125,000 pregnant women in Sweden, researchers found that the risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life is higher in women with intrahepatic cholestasis of pregnancy (ICP) than in women without this condition.

9 Jul 2015

Guselkumab drug more effective than current standard of care for psoriasis

A phase II clinical trial led by Northwestern Medicine investigators shows that a new psoriasis drug called guselkumab has greater efficacy than the current standard of care for the chronic skin condition.

9 Jul 2015

Common arthritis drug could help to treat patients with blood cancers

Scientists at the University of Sheffield have discovered that a common drug given to arthritis sufferers could also help to treat patients with blood cancers.

7 Jul 2015

Avexxin concludes second phase I/IIA study in patients suffering from mild-to-moderate psoriasis

Avexxin AS, a therapeutic company focusing on the discovery and development of novel small molecule therapeutics for patients suffering from chronic inflammatory conditions, announces the completion of a second phase I/IIa study showing Proof-of-Concept in man.

2 Jul 2015

Frequent consumption of citrus fruits may increase risk of skin cancer

A new analysis of dietary patterns among more than 100,000 Americans suggests that frequent consumption of citrus -- namely whole grapefruit and orange juice -- may be associated with an increased risk of melanoma.

2 Jul 2015

Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Both spouses and first-degree relatives of patients with celiac disease are at increased risk of nonceliac autoimmune disease, according to a study in the July issue of Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. This risk represents a mixture of genetic, environmental and ascertainment bias mechanisms.

1 Jul 2015

Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow the initiation of a Phase I clinical study.

29 Jun 2015

Psoriasis News and Research

Latest Psoriasis News and Research

Stoptober campaign focuses on skin disease research

Immune Pharmaceuticals’ CEO establishes stock trading plan

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Janus collaborates with Roche to develop TLR inhibitor to address several autoimmune diseases

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Risk of hepatobiliary cancer higher in women with intrahepatic cholestasis of pregnancy

Scientific consensus paper highlights health benefits of UV exposure and vitamin D

Results of IPC survey identifying 21 psoriasis research priorities published in British Journal of Dermatology

World Health Organization recognizes unique pharmacological nature of Can-Fite's CF101, grants new generic name

Does dandruff cause psychological distress? An interview with Dr Anjali Mahto

National Psoriasis Foundation introduces patient-centered research network

AnaptysBio announces completion of oversubscribed $40MM Series D financing round

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Risk of hepatobiliary cancer, cardiovascular diseases later in life is higher in women with ICP

Guselkumab drug more effective than current standard of care for psoriasis

Common arthritis drug could help to treat patients with blood cancers

Avexxin concludes second phase I/IIA study in patients suffering from mild-to-moderate psoriasis

Frequent consumption of citrus fruits may increase risk of skin cancer

Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Psoriasis News and Research

Latest Psoriasis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in